SLC5A2 and chronic kidney disease: Clinical studies, such as the DAPA-CKD and CREDENCE trials, further validate the efficacy of these mechanisms, demonstrating that SGLT-2 inhibitors significantly reduce the risk of renal function deterioration in non-diabetic CKD patients and improve overall quality of life, making them an important therapeutic option in CKD management (Figure 1).